Divalproex extended-release in adolescent migraine prophylaxis: Results of a randomized, double-blind, placebo-controlled study

Headache

Volumn 48, Issue 7, 2008, Pages 1012-1025

  Apostol, George ^a   Cady, Roger K ^b   Laforet, Genevieve A ^a   Robieson, Weining Z ^a   Olson, Evelyn ^a   Abi Saab, Walid M ^a   Saltarelli, Mario ^a  

^a ABBOTT LABORATORIES   (United States)

^b HEADACHE CARE CENTER   (United States)

Author keywords

Adolescents; Divalproex sodium; Migraine prophylaxis; Pediatric migraine

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; CYPROHEPTADINE; FLUNARIZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PSYCHOSTIMULANT AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ABDOMINAL PAIN; ADOLESCENT; ADOLESCENT DISEASE; AMMONIA BLOOD LEVEL; ARTICLE; ATTENTION DEFICIT DISORDER; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; INFLUENZA; LARYNX PAIN; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MIGRAINE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTION; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SUSTAINED RELEASE FORMULATION; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VIRUS INFECTION; VOMITING; WEIGHT GAIN;

ADOLESCENT; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; VALPROIC ACID;

EID: 46749122298     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01081.x     Document Type: Article

References (38)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
2. Heng K, Wirrell E. Sleep disturbance in children with migraine. J Child Neurol. 2006 21 : 761 766.
3. D'Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia. 2006 26 : 691 696.
4. Victor S, Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database Syst Rev. 2003 4 : CD002761.
5. Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children: A systematic review of medication trials. Pediatrics. 2005 116 : e295 e302.
6. Eiland LS, Jenkins LS, Durham SH. Pediatric migraine: Pharmacologic agents for prophylaxis. Ann Pharmacother. 2007 41 : 1181 1190.
7. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004 63 : 2215 2224.
8. Klapper J. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997 17 : 103 108.
9. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995 52 : 281 286.
10. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002 58 : 1652 1659.
11. Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F. Sodium valproate versus propranolol in paediatric migraine prophylaxis. Eur J Paediatr Neurol. 2005 9 : 333 338.
12. Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache. 2000 40 : 672 676.
13. Fragoso YD. Low dose of sodium divalproate for the treatment of migraine. Med Gen Med. 2003 5 : 32.
14. Mendizabal JE. Extended-release divalproex sodium improves the quality of life of adolescent migraineurs. Headache. 2002 42 : 327 328.
15. Pakalnis A, Greenberg G, Drake ME Jr., Paolichi J. Pediatric migraine prophylaxis with divalproex. J Child Neurol. 2001 16 : 731 734.
16. Serdaroglu G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. Headache. 2002 42 : 819 822.
17. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia. 1998 18 : 52 56.
18. Dutta S, Zhang Y, Conway JM, et al. Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol. 2004 30 : 330 337.
19. Herzog AG. Menstrual disorders in women with epilepsy. Neurology. 2006 66 (6 Suppl. 3 S23 S28.
20. Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drugs: A review of the evidence. J Clin Psychopharmacol. 2004 24 : 322 334.
21. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000 20 : 765 786.
22. Hershey AD, Powers SW, Vockell AL, LeCates S, Kabbouche MA, Maynard MK. PedMIDAS: Development of a questionnaire to assess disability of migraines in children. Neurology. 2001 57 : 2034 2039.
23. Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: A pooled analysis of efficacy and safety. Headache. 2006 46 : 1503 1510.
24. Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia. 2003 23 : 487 490.
25. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005 45 : 232 239.
26. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: The scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2005 25 : 124 131.
27. Verrotti A, Greco R, Matera V, Altobelli E, Morgese G, Chiarelli F. Platelet count and function in children receiving sodium valproate. Pediatr Neurol. 1999 21 : 611 614.
28. Delgado MR, Riela AR, Mills J, Browne R, Roach ES. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol. 1994 9 : 311 314.
29. Allarakhia IN, Garofalo EA, Komarynski MA, Robertson PL. Valproic acid and thrombocytopenia in children: A case-controlled retrospective study. Pediatr Neurol. 1996 14 : 303 307.
30. Conley EL, Coley KC, Pollock BG, Dapos SV, Maxwell R, Branch RA. Prevalence and risk of thrombocytopenia with valproic acid: Experience at a psychiatric teaching hospital. Pharmacotherapy. 2001 21 : 1325 1330.
31. Abbott Laboratories. Depakote ER (divalproex sodium extended-release tablets) prescribing information. North Chicago, IL 60064, USA. October 2006.
32. Altunbasak S, Baytok V, Tasouji M, Herguner O, Burgut R, Kayrin L. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol. 1997 12 : 461 463.
33. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002 17 : 367 373.
34. Wyllie E, Wyllie R, Rothner AD, Erenberg G, Cruse RP. Valproate-induced hyperammonemia in asymptomatic children. Cleve Clin Q. 1983 50 : 275 277.
35. Maranda B, Cousineau J, Allard P, Lambert M. False positives in plasma ammonia measurement and their clinical impact in a pediatric population. Clin Biochem. 2007 40 : 531 535.
36. Wu A. Tietz Clinical Guide to Laboratory Tests, 4th edn. St Louis, MO : Saunders/Elsevier 2006.
37. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006 59 : 1078 1086.
38. Rättyä J, Pakarinen AJ, Knip M, Repo-Outakoski M, Myllylä VV, Isojärvi JI. Early hormonal changes during valproate or carbamazepine treatment: A 3-month study. Neurology. 2001 57 : 440 444.